Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ending June 30, 2021
June 25, 2021 at 07:03 am EDT
Share
Shanghai Haohai Biological Technology Co., Ltd. provided unaudited consolidated earnings guidance for the six months ending June 30, 2021. For the six months, the Group is expected to record an unaudited net profit attributable to shareholders of the Company of approximately RMB 220,000,000 to RMB 250,000,000 during the Reporting Period, representing an increase of approximately RMB 192,472,800 to RMB 222,472,800, or approximately 699.21% to 808.19%, as compared to that in 2020. The unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB 210,000,000 to RMB 240,000,000, representing an increase of approximately RMB 202,170,100 to RMB 232,170,100, or approximately 2,582.03% to 2,965.17%, as compared to that in 2020 .
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.